Skip to Content

Bupivacaine Liposome Dosage

Medically reviewed on July 26, 2017.

Applies to the following strengths: 1.3% (13.3 mg/mL)

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Pain

The manufacturer product information should be consulted.

Maximum dose: 266 mg once

-Bunionectomy dosing example: 106 mg (8 mL) administered as 7 mL infiltrated into the tissues surrounding the osteotomy and 1 mL into the subcutaneous tissue.
-Hemorrhoidectomy dosing example: 266 mg (20 mL) diluted with 10 mL of saline (30 mL total) and injected by visualizing the anal sphincter as a clock face and slowly infiltrating one 5 mL aliquot into each of the even numbers.

Use: Administration into the surgical site to produce postsurgical analgesia.

Renal Dose Adjustments

Caution recommended

Liver Dose Adjustments

Use with caution


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-This drug is intended for single-dose administration only.
-Inject slowly into the soft tissues of the surgical site with frequent aspiration to check for blood and minimize the risk of intravascular injection.
-Administer with a 25 gauge or larger bore needle.
-May administer undiluted or diluted.
-Diluted suspensions of this drug should be used within 4 hours of preparation in a syringe.
-Do not use vial if stopper is bulging.

Storage requirements:
-Refrigerate between 2 and 8C (36 and 46F); may be held at 20 to 25C (68 to 77F) for up to 30 days in sealed, unopened vials; vials should not be re-refrigerated.
-Do not freeze or expose to high temperatures (greater than 40C or 104F) for an extended period.

Reconstitution/preparation techniques:
-May dilute to increase volume up to a final concentration of 0.89 mg/mL (e.g., 1:14 dilution by volume) with normal (0.9%) saline or lactated Ringer's solution.
-Vials of this drug should be inverted multiple times to re-suspend the particles immediately prior to withdrawal from the vial.

IV compatibility:
-Administration of this drug may follow the administration of lidocaine after a delay of 20 minutes or more.
-Bupivacaine hydrochloride and this drug may be administered simultaneously in the same syringe, and bupivacaine hydrochloride may be injected immediately before this drug as long as the ratio of the milligram dose of bupivacaine hydrochloride to this drug does not exceed 1:2.
-This drug should not come into contact with antiseptics such as povidone iodine in solution.

-Dose is based on size of surgical site, volume required to cover the area, individual patient factors that may impact the safety of an amide local anesthetic, and a maximum dose of 266 mg.
-Different formulations of bupivacaine are not bioequivalent even if the milligram strength is the same; it is not possible to convert dosing from any other bupivacaine formulations to this drug.

Monitoring: Perform careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness after injection of this drug.

Patient advice:
-Advise pregnant women of the potential risks to a fetus.
-Inform patients that this drug can cause temporary loss of sensation or motor activity.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.